These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Expert Insights from a Delphi-driven Neurologists' Panel: Real-world Mexiletine use in Patients with Myotonic Disorders in Italy. Lidonnici D; Brambilla P; Ravasio R; Zozulya-Weidenfeller A; Beiderbeck A; van Aswegen M; Oliveira R; Sansone VA J Neuromuscul Dis; 2024; 11(2):411-423. PubMed ID: 38306059 [TBL] [Abstract][Full Text] [Related]
7. Voltage-Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues. Catalano A; Franchini C; Carocci A Curr Med Chem; 2021; 28(8):1535-1548. PubMed ID: 32364065 [TBL] [Abstract][Full Text] [Related]
8. A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia. D'Mello S; Shum L Eur J Hosp Pharm; 2016 Nov; 23(6):359-363. PubMed ID: 31156883 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of mexiletine versus placebo in patients with myotonia: a systematic review and meta-analysis. Elettreby AM; Elnaga AAA; Alsaied MA; Ewis DK; Sharkawy AM; Fareed R; Alderbi GM Neurol Sci; 2024 Aug; 45(8):3989-4001. PubMed ID: 38403671 [TBL] [Abstract][Full Text] [Related]
10. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Groh WJ Neurology; 2011 Jan; 76(4):409; author reply 409. PubMed ID: 21263144 [No Abstract] [Full Text] [Related]
11. Evaluation of mexiletine effect on conduction delay and bradyarrhythmic complications in patients with myotonic dystrophy type 1 over long-term follow-up. Vio R; Zorzi A; Bello L; Bozzoni V; Botta A; Rivezzi F; Leoni L; Migliore F; Bertaglia E; Iliceto S; Pegoraro E; Corrado D; Calore C Heart Rhythm; 2020 Nov; 17(11):1944-1950. PubMed ID: 32525073 [TBL] [Abstract][Full Text] [Related]
12. Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. Stunnenberg BC; Raaphorst J; Groenewoud HM; Statland JM; Griggs RC; Woertman W; Stegeman DF; Timmermans J; Trivedi J; Matthews E; Saris CGJ; Schouwenberg BJ; Drost G; van Engelen BGM; van der Wilt GJ JAMA; 2018 Dec; 320(22):2344-2353. PubMed ID: 30535218 [TBL] [Abstract][Full Text] [Related]
13. Clinical Care Recommendations for Cardiologists Treating Adults With Myotonic Dystrophy. McNally EM; Mann DL; Pinto Y; Bhakta D; Tomaselli G; Nazarian S; Groh WJ; Tamura T; Duboc D; Itoh H; Hellerstein L; Mammen PPA J Am Heart Assoc; 2020 Feb; 9(4):e014006. PubMed ID: 32067592 [TBL] [Abstract][Full Text] [Related]
14. Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2. Mousele C; Matthews E; Pitceathly RDS; Hanna MG; MacDonald S; Savvatis K; Carr A; Turner C Neurol Clin Pract; 2021 Oct; 11(5):e682-e685. PubMed ID: 34840883 [TBL] [Abstract][Full Text] [Related]
15. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Trivedi JR; Bundy B; Statland J; Salajegheh M; Rayan DR; Venance SL; Wang Y; Fialho D; Matthews E; Cleland J; Gorham N; Herbelin L; Cannon S; Amato A; Griggs RC; Hanna MG; Barohn RJ; Brain; 2013 Jul; 136(Pt 7):2189-200. PubMed ID: 23771340 [TBL] [Abstract][Full Text] [Related]
16. Treatment of myotonia with antiarrhythmic drugs. Kwieciński H; Ryniewicz B; Ostrzycki A Acta Neurol Scand; 1992 Oct; 86(4):371-5. PubMed ID: 1455983 [TBL] [Abstract][Full Text] [Related]
17. Blockers of Skeletal Muscle Na De Bellis M; Boccanegra B; Cerchiara AG; Imbrici P; De Luca A Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614292 [TBL] [Abstract][Full Text] [Related]
18. The Dystrophic and Nondystrophic Myotonias. Sansone VA Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1889-1915. PubMed ID: 27922499 [TBL] [Abstract][Full Text] [Related]
19. Impact of restricted access to, and low awareness of, mexiletine on people with myotonia: a real-world European survey. Díaz-Manera J; Urtizberea JA; Schey C; Kole A; von Gallwitz P; Whiting A; Foerster D; Zozulya-Weidenfeller A Neuromuscul Disord; 2023 Feb; 33(2):208-217. PubMed ID: 36706619 [TBL] [Abstract][Full Text] [Related]
20. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. Stunnenberg BC; Woertman W; Raaphorst J; Statland JM; Griggs RC; Timmermans J; Saris CG; Schouwenberg BJ; Groenewoud HM; Stegeman DF; van Engelen BG; Drost G; van der Wilt GJ BMC Neurol; 2015 Mar; 15():43. PubMed ID: 25880166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]